This Article Abstract Full Text (PDF) All Versions of this Article: 89/4/317    most recent hh1601.094625v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ying, W.-Z. Articles by Sanders, P. W. Search for Related Content PubMed PubMed Citation Articles by Ying, W.-Z. Articles by Sanders, P. W. Related Collections Animal models of human disease Hypertension - basic studies Physiological and pathological control of gene expression

(Circulation Research. 2001;89:317.)
© 2001 American Heart Association, Inc.

Molecular Medicine

Nitric Oxide Synthase (NOS2) Mutation in Dahl/Rapp Rats Decreases Enzyme Stability

Wei-Zhong Ying, Hongli Xia, Paul W. Sanders

From the Nephrology Research and Training Center, Comprehensive Cancer Center, and Cell Adhesion and Matrix Research Center, Division of Nephrology, Department of Medicine, and Department of Physiology and Biophysics, University of Alabama at Birmingham, and Department of Veterans Affairs Medical Center, Birmingham, Ala.

Correspondence to Paul W. Sanders, MD, Division of Nephrology/Department of Medicine, 642 Lyons-Harrison Research Building, 701 South 19th St, University of Alabama at Birmingham, Birmingham, AL 35294-0007. E-mail psanders{at}uab.edu

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
The pathogenesis of salt-sensitive hypertension remains poorly defined, but a role for nitric oxide (NO) has been suggested. The Dahl/Rapp salt-sensitive rat possesses a defect in NO synthesis that is overcome by supplementation with L-arginine, which increases NO and cGMP production and prevents salt-sensitive hypertension. An S714P mutation of inducible NO synthase (NOS2) was subsequently identified. The current report examined the functional significance of an S714P mutation in NOS2. COS-7 cells were transiently transfected with cDNA of wild-type NOS2 and S714P and S714A mutants of NOS2, and enzyme function was determined. Whereas steady-state mRNA levels did not differ, immunoblot analysis demonstrated decreased levels of NOS2 protein. Metabolic labeling experiments confirmed a reduced half-life of the S714P mutation. Nitrite production, which was dependent on the concentration of L-arginine in the medium, was diminished in cells transfected with the S714P mutant, compared with the wild type and the S714A mutant. These data provide a biochemical explanation of the physiological abnormalities of NOS2 in the Dahl/Rapp salt-sensitive rat and suggest that a posttranslational mechanism involving the proteasome may be responsible for the diminished NO production observed in response to increased dietary salt intake in these animals.

Key Words: hypertension • nitric oxide • nitric oxide synthase • proteasome • lactacystin

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Almost a quarter of the population of the United States has hypertension.¹ Although African-Americans are much more likely to exhibit salt sensitivity, 50% to 75% of the total hypertensive population demonstrate salt sensitivity; that is, blood pressure is altered as dietary salt intake is changed.² Breeding studies in rats have confirmed that there is a genetic susceptibility to develop salt-sensitive hypertension.^3,4 Whereas multiple genes are involved in the blood pressure response to changes in dietary salt intake, increasing evidence supports an important role of altered synthesis of nitric oxide (NO) in salt sensitivity. NO synthesis occurs in the vessel wall^5–7 and in the kidney^8–10 and serves as a locally produced vasodilator^5–7,11 and natriuretic factor.^12–16 Kidney production of NO appears to be particularly important in blood pressure regulation, because infusion of N^G-nitro-L-arginine methyl ester directly into the renal medulla causes sodium retention and increased blood pressure.¹⁷ Thus, NO is uniquely situated to control blood pressure responses to increased salt intake.

Dietary salt modulates NO production in healthy humans¹⁸ and in normotensive rats.^19,20 An increase in salt intake increases NO production.^19,20 Along with determining the blood pressure response to a high-salt diet,^12,19,21,22 the renal vascular resistance and renal functional changes that occur with an increase in dietary salt are also modulated by NO.^12,13,23 In contrast to normotensive rats, the increase in NO production is absent in Dahl/Rapp salt-sensitive (S) rats, an inbred strain of rat that manifests salt-sensitive hypertension. However, when provided with L-arginine, production of NO and cGMP increases and salt-sensitive hypertension is completely prevented.^19,24–26 Decreased serum levels of L-citrulline and L-arginine and alteration of the rate-limiting enzymes of the urea cycle have not been identified in S rats.²⁷ The combined studies leave little doubt about a central role of NO synthesis in development of salt-sensitive hypertension in S rats.

The three known isoforms of NO synthase (NOS) are present in the kidney^8,9,28–31 and respond to changes in dietary salt.^28–30,32 NOS1, the neuronal isoform, is localized primarily in the macula densa⁸ and actually decreases when dietary salt is increased²⁸; therefore, activity of NOS1 cannot explain the increase in NO production that occurs with an increase in salt intake. NOS3, which is also referred to as the endothelial isoform, increases in aorta and glomeruli as dietary salt is increased.^30,32 NOS2 is expressed by cytokine induction, but interestingly is present in the normal kidney, suggesting a different mechanism of regulation in the kidney.^9,29,31 Both NOS3 and NOS2 are involved in the renal response to changes in dietary salt.

NOS2 appears to be involved in salt-sensitive hypertension. An increase in dietary salt increased the renal expression of NOS2.²⁹ Lüscher’s group demonstrated that, on a diet that contained a high salt content, renal cortical and medullary calcium-independent NO production increased in Dahl/Rapp salt-resistant (R) rats but was impaired in S rats.³³ Administration of highly specific inhibitors of NOS2 to R rats produced salt-sensitive hypertension in these animals, which are known to be very salt-resistant.²¹ Careful studies by Tan et al³⁴ also showed an important role of NOS2 in increasing NO production and preventing salt-sensitive hypertension in R rats and in decreasing salt sensitivity in S rats. In early studies, this laboratory hypothesized a role for NOS2 in salt-sensitive hypertension, because dexamethasone, which has been shown to inhibit induction of Nos2,³⁵ also prevented the antihypertensive effects of L-arginine in S rats.¹⁹ NOS2 from vascular smooth muscle cells in culture produced less NO than NOS2 from cells of Sprague-Dawley and R rats. Subsequently, a single point mutation in NOS2 cDNA from S rats was identified. This TC transversion resided between the flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD) binding sites of the molecule and produced an amino acid substitution of proline for serine at position 714.²⁶ The purpose of the present study was to determine the role of the S714P mutation in NOS2 function.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Site-Directed Mutagenesis
Rat NOS2 cDNA was a generous gift from Prof Göran K. Hansson (Karolinska Institute, Stockholm, Sweden). Site-directed mutagenesis was accomplished using a kit (QuikChange Site-Directed Mutagenesis Kit, Stratagene). Briefly, using a 523-bp cloned fragment of NOS2 as template, synthetic complementary oligonucleotide primers (Operon) containing the desired mutations were extended using PfuTurbo DNA polymerase during low-cycle temperature cycling. Primers used to generate the S714P mutation were the following: 5'-CCCAGAGCCCAGAGCCTCTAGACCTCAA-CAAAGC-3' and 5'-GCTTTGTTGAGGTCTAGAGGCT-CTGGGCTCTGGG-3'. Primers used to generate the S714A mutation were the following: 5'-CCCAGAGCCCAGGCTCTCTA-GACCTCAACAAAGC-3' and 5'-GCTTTGTTGAGGTCTA-GAGAGCCTGGGCTCTGGG-3'. The mutated DNA was cloned in standard fashion. The entire 523-bp fragment was sequenced (ABI Prism), and the desired mutations were confirmed. The fragments were then ligated into NOS2 cDNA (from -57 to 4120) in pRc/CMV2 (Invitrogen).

Transient Transfection of COS-7 Cells
COS-7 cells (CRL-1651, SV40-transformed African green monkey kidney cells, American Type Culture Collection) 70% confluent were simultaneously transfected with mixtures of pRc/CMV2 containing 12 µg of cDNA under study (wild-type, S714P, and S714A mutations), 50 µL transfection reagent (GenePORTER reagent, Gene Therapy Systems), and 5 mL serum-free medium for 5 hours. FBS (20%; Intergen) was then added, and assays were performed as described below.

Northern and Immunoblot Analyses of NOS2 Expression
Northern analysis was performed as described previously,^30,36,37 using 15 µg of total RNA. Membranes were hybridized with a ³²P-labeled, 1-kb cDNA fragment of NOS2, followed by rehybridization with ³²P-labeled human GAPDH probe obtained through American Type Culture Collection. Bands were quantified using densitometry (model 620 video densitometer, Bio-Rad).

To examine protein expression, transfected COS-7 cells were lysed in buffer that contained 0.3 mol/L sucrose; 1.0% NP40 (vol/vol); 50 µmol/L PMSF; in mmol/L, HEPES 10, EDTA 0.1, DTT 1, and Tris/HCl (pH 7.6) 50; and 10 µg/mL each of aprotinin, leupeptin, and trypsin inhibitor (all from Sigma). Cytosolic extracts were obtained by centrifugation of the lysates at 100 000g for 1 hour. Protein concentration was determined using a kit (Micro BCA Protein Assay Reagent Kit, Pierce). Western blotting was performed in standard fashion,^30,36,37 using 10 µg of total protein. NOS2 was identified using a mouse anti-NOS2 monoclonal antibody (Transduction Laboratories), 1:500 dilution, followed by goat anti-mouse IgG conjugated to peroxidase (Bio-Rad), 1:20 000 dilution.

Determination of Production of NO Metabolites
Twenty-four hours after initiation of simultaneous transfections of plates of COS-7 cells with plasmids containing the wild-type and S714P and S714A mutants, medium was aspirated and replaced with 10 mL of DMEM that contained varying concentrations (0 to 200 µmol/L) of L-arginine. After an additional 48 hours, medium was harvested and assayed for nitrite in standard fashion using Griess reagent, as described previously.^25,30 Each experiment was performed in duplicate at each concentration of L-arginine and was averaged. Five separate experiments were performed.

NOS2 Enzyme Activity Assay
NOS2 was purified from COS-7 cells 72 hours after transfection, using standard biochemical purification procedures that had been proven successful in purification of NOSs.^38–41 Briefly, NOS2 was isolated from cytosolic extracts (25 mg total protein) using a 2',5'–ADP-Sepharose 4B (Pharmacia) column, followed by a calmodulin affinity column. Arginine was left out of all buffers beginning with the calmodulin column. Purity of the preparations was demonstrated by SDS-PAGE along with Western blotting to confirm identity of the bands as NOS2. Concentration of protein in each sample was determined using a kit (Micro BCA Protein Assay Reagent Kit).

NOS2 activity was determined by the rate of formation of [³H]L-citrulline from [³H]L-arginine as described,⁴² with modifications as follows. Enzyme assays contained 2 µg NOS2; in mmol/L, NADPH 0.5, CaCl₂ 1.25, and HEPES (pH 7.6) 50; in µmol/L, FAD 10, FMN 0.5, calmodulin 7.5, and (6R)-5,6,7,8-tetrahydro-L-biopterin dihydrochloride (BH4) 15; and 1 µCi [³H]L-arginine (NEN/DuPont). Except for BH4, which was obtained from Schirks Laboratories, all reagents came from Sigma. The concentration of L-arginine was varied in these experiments between 0 and 100 µmol/L. In preliminary studies, production of [³H]L-citrulline was linear over 30 minutes of observation. The kinetics experiments were therefore terminated at 20 minutes. The reaction was performed at 37°C and was stopped by adding 2 mL of ice-cold 20 mmol/L HEPES (pH 5.5) containing 5 mmol/L EDTA. The sample was applied onto a Dowex AG 50W-X8 column that had been preequilibrated with 20 mmol/L HEPES (pH 5.5). Activity of eluate, which contained [³H]L-citrulline, was quantified by liquid scintillation spectrometry.

Metabolic Labeling Study to Determine NOS2 Half-Life
Metabolic labeling of NOS2 was performed in standard fashion, following published methods.^43,44 Seventy-two hours after transfection, COS-7 cells were incubated for 20 minutes at 37°C in MEM (MEM Select-Amine Kit, GibcoBRL), which did not contain cysteine, methionine, or serum. Cells were pulse-labeled for 30 minutes in 150 µL of MEM supplemented with [³⁵S]cysteine and [³⁵S]methionine (Tran³⁵S-label, ICN Biochemicals), 300 µCi/mL. Pulse-labeled cells were incubated for 0, 6, 12, 18, and 24 hours at 37°C in complete medium. Cell lysates (n=4 in each group) were prepared in standard fashion using radioimmunoprecipitation assay buffer containing protease inhibitors (Complete, Boehringer Mannheim). Lysates (100 µg total protein per 200 µL) were incubated with 4 µL mouse anti-NOS2 monoclonal antibody (Transduction Laboratories), 1:50 dilution in Tris-buffered saline, overnight at 4°C, and then incubated with 20 µL of protein A–Sepharose beads (CL-4B, Amersham Pharmacia Biotech) for 2 hours at 4°C with gentle rocking. The beads were washed four times with 500 µL of lysis buffer, and ³⁵S activity was quantified by liquid scintillation spectrometry. In other experiments, 400 µg of total protein lysates from pulse-labeled cells were incubated with 8 µL anti-NOS2 monoclonal antibody, 1:50 dilution, and then protein A–Sepharose beads. The immunoprecipitated proteins were solubilized in loading buffer and resolved using SDS-PAGE. After exposure to x-ray film, density of each band was quantified.

Role of the Proteasome in NOS2 Degradation
Forty-eight hours after simultaneous transfections of plates of COS-7 cells with plasmids containing the wild-type and S714P and S714A mutants, the medium was aspirated and replaced with DMEM supplemented with 20 µmol/L cycloheximide (an inhibitor of protein synthesis), and either 10 µmol/L clasto-lactacystin ß-lactone (the active metabolite of lactacystin^45–47) or 0.1% DMSO, which served as a vehicle control. All of these chemicals came from Sigma. COS-7 cells were harvested at 0, 6, 12, 18, and 24 hours after the change of the medium. After washing with ice-cold PBS, cells were lysed in three volumes of lysis buffer (in mmol/L, HEPES [pH 7.4] 10, DTT 1, EDTA 2, and Na₃VO₄ 10; 0.3 mol/L sucrose; 50 µmol/L PMSF; in µg/mL, leupeptin 10, aprotinin 2, and trypsin inhibitor 10; and 1% NP40). The lysates were centrifuged at 16 000g for 10 minutes, and the supernatant was harvested. The protein concentration was determined using a kit (Micro BCA Protein Assay Reagent Kit). Fifteen micrograms of total protein was subjected to electrophoresis using 8% SDS-polyacrylamide gels and then transferred onto nitrocellulose membranes. The membranes were probed with an anti-NOS2 polyclonal antibody (Transduction Laboratories), 1:1000 dilution. An anti-mouse IgG conjugated to peroxidase (Roche Molecular Biochemicals), 1:10 000 dilution, was used as the secondary antibody. The bands were visualized by the use of enhanced chemiluminescence reagent and X-OMAT film (Eastman Kodak Co). The intensity of the signals was quantified by densitometry (Bio-Rad).

Statistical Analysis
All data are mean±SE. Statistical differences were determined using either the unpaired t test or 1-way ANOVA with standard post hoc testing (Statview, version 5.0, SAS Institute, Inc). A P value of <0.05 assigned significance.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
S714P and S714A mutations of NOS2 were created, and activities of these mutant NOS2 enzymes were compared with wild-type NOS2. The alanine mutation was generated to determine whether serine phosphorylation or alteration in structure produced by replacement of serine with proline was the cause of altered NOS2 activity. Northern analysis showed that steady-state mRNA levels of the three NOS2 enzymes by the transfected COS-7 cells did not differ (Figure 1). Using a monoclonal anti-NOS2 antibody, however, Western blotting demonstrated a decrease in protein expression of the S714P mutant (Figure 1). This disparity prompted an analysis of the biological half-life of the S714P mutant. To address this hypothesis, metabolic labeling of NOS2 was performed 72 hours after transfection of COS-7 cells. The amount of protein labeled at the initial time point did not differ among the three groups, suggesting that a posttranslational mechanism was involved in altered expression of the S714P mutant (Figure 2). Degradation rates of wild-type NOS2 and S714A did not differ, but were greater (P<0.05) at every time point tested from 6 to 24 hours for the S714P mutant.

View larger version (30K): [in this window] [in a new window]   Figure 1. Northern analysis (gel at top) showed that steady-state mRNA levels did not differ among the three groups expressing wild-type NOS2 and S714P and S714A mutations (n=4 in each group). Immunoblot analysis demonstrated single bands migrating at the expected 130 000 size in all three groups. NOS2 protein expression was diminished in S714P group. Mr indicates molecular weight.

View larger version (17K): [in this window] [in a new window]   Figure 2. Pulse-chase experiment demonstrating that the half-life of the S714P mutant was diminished compared with wild-type NOS2 and the S714A mutant. Gel demonstrated that a single band was immunoprecipitated. Graph shows immuno-precipitable 35S counts in each group (n=4 experiments each).

To determine whether the proteasome degraded NOS2, clasto-lactacystin ß-lactone was added along with cycloheximide to the medium of cells expressing NOS2, S714P, and S714A. Cells treated with cycloheximide alone showed findings that were consistent with the metabolic labeling experiments, with the S714P mutant disappearing from the cytoplasm faster than wild-type and S714A mutant (Figure 3). Addition of clasto-lactacystin ß-lactone reduced degradation rates of the S714P mutant to levels comparable with those of the other two proteins.

View larger version (23K): [in this window] [in a new window]   Figure 3. Top, Addition of cycloheximide (CHX) to medium confirmed the pulse-chase study, which showed accelerated removal of S714P mutant from cytoplasm. These data also demonstrated that new protein synthesis was not required to produce this effect. Bottom, Addition of clasto-lactacystin ß-lactone (LAC), which inhibits the proteasome, along with CHX, to medium. Inhibition of the proteasome inhibited degradation of wild-type NOS2 and S714A mutant and prevented accelerated removal of the S714P mutant from the cytoplasm.

Nitrite production rates by cells transfected with the S714P mutation were lower (P<0.05) than nitrite production rates by cells transfected with either the wild-type NOS2 or the S714A mutation (Figure 4). Initial kinetic analysis of the S714P mutant using cytoplasmic preparations demonstrated no change in K_m, but a decrease in V_max, compared with the wild-type NOS2 and the S714A mutant (data not shown). These findings were consistent with a decrease in cytoplasmic protein concentration of the mutant. Kinetic analysis was therefore performed using purified NOS2 enzymes to determine whether an intrinsic abnormality in enzyme function was present. Under these conditions, neither K_m (in µmol/L, 26.1±4.5 for wild-type NOS2; 27.1±4.7 for S714P; and 30.9±3.2 for S714A) nor V_max (in nmol of citrulline/min per mg NOS2, 1283±407 for wild-type NOS2, 1370±373 for S714P, and 1529±421 for S714A) differed among the three enzymes. Under comparable experimental conditions, Yui et al³⁸ observed the similar K_m (32.2 µmol/L) and V_max (1052 nmol/min per mg protein) for purified rat NOS2.

View larger version (15K): [in this window] [in a new window]   Figure 4. Twenty-four hours after simultaneous transient transfections of COS-7 cells with cDNA specimens under study, nitrite accumulation in medium was determined over a 48-hour period. Rate of production of nitrite after transfection was less (P<0.05) in COS-7 cells transfected with S714P mutation compared with wild-type and S714A cDNA. n=5 studies (data in each study consisted of averages of experiments performed in duplicate) at each L-arginine concentration.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
The purpose of the present study was to determine whether an S714P mutation identified in Nos2 of S rats altered the function of the enzyme. Expression of this mutation, along with wild-type NOS2 and an S14A mutant, was performed using COS-7 cells. The initial observation was that the amount of NO produced, as determined by nitrite accumulation in the medium, did not differ between wild-type NOS2 and the S714A mutant but was less with the S714P mutant. Subsequent kinetic experiments showed an unexpected decrease in V_max, but no change in K_m of the S714P mutant. To determine the cause of the altered expression, Northern analysis was performed and demonstrated no alteration in steady-state levels of mRNA among the three groups. Western analysis, however, showed a decrease in protein expression of the S714P mutant, compared with the wild-type NOS2 and S714A mutant. To address the mechanism of altered expression, standard pulse-chase labeling experiments were performed. These experiments showed that the amount of protein labeled initially did not differ among the three groups. Thus, a posttranslational event was responsible for the altered expression of the S714P mutant. The subsequent "chase" portion of the experiment confirmed that the biological half-life of this mutant was reduced, compared with the other two groups. Addition of cycloheximide to the medium produced similar results. These data were supported by experiments that examined enzyme kinetics after purification of NOS2. In these studies that used purified NOS2 and not cytoplasmic extracts, differences in V_max or K_m were not observed.

To determine the mechanism of degradation of NOS2, clasto-lactacystin ß-lactone, a cell-permeable and irreversible inhibitor of the proteasome,^45–47 was added to the medium along with cycloheximide. These experiments demonstrated that clasto-lactacystin ß-lactone, the active metabolite of lactocystin,^46,47 inhibited the degradation of wild-type NOS2 and the S714P and S714A mutants. Thus, the data confirmed a previous study that suggested that NOS2 was degraded by the proteasome⁴⁸ and further showed that the S714P mutant was removed more rapidly from the cytoplasm by the proteasome. The mechanism by which the S714P mutant was sensitized to degradation by the proteasome remained unclear but was not related to a serine phosphorylation event, because mutating the serine to alanine did not alter enzyme function or half-life, compared with wild-type NOS2.

Several laboratories have demonstrated increased NO production in vivo in response to dietary salt.^18–20,33 Physiological studies have shown that NOS2 is involved in the increase in NO synthesis and blood pressure response to dietary salt.^18,21,25,29 In addition, an alteration in NOS2 function has been suggested in S rats.²⁵ NO production does not increase when dietary salt is increased in S rats, which manifest salt-sensitive hypertension. These animals are unique in that administration of L-arginine "cures" the salt sensitivity.^19,25–27 NO production is particularly important in the kidney, where it serves an important natriuretic function.^12–16 R rats responded to an increase in dietary salt by increasing renal production of NO through calcium-independent NOS activity. In contrast, renal calcium-independent NOS activity was impaired in kidneys of S rats.³³ The importance of NOS2 in blood pressure regulation as dietary salt is increased was further shown by studies that showed R rats develop salt-sensitive hypertension with administration of highly selective inhibitors of NOS2.²¹ NO production by NOS2 from primary cultures of vascular smooth muscle cells from S rats is less than NO production by cells from Sprague-Dawley and R rats.²⁶ In addition, a point mutation in NOS2 has been found in S rats.²⁶ Thus, abundant evidence supports a role for NOS2 in the increase in NO production in response to dietary salt and further suggests defective NOS2 function in generation of salt-sensitive hypertension. Although it is attractive to consider NOS2 as a candidate gene in salt-sensitive hypertension, genetic analyses to determine the role of Nos2 in blood pressure regulation in humans and rats provided conflicting results. Using sibling-pair analysis, a susceptibility locus for human hypertension was identified on human chromosome 17, which is syntenic with the region of rat chromosome 10 that contains Nos2.⁴⁹ In a recent study, however, association or linkage of two polymorphic markers at the Nos2A locus with hypertension was not confirmed specifically in an Australian Anglo-Caucasian population of subjects.⁵⁰ The phenotype of salt sensitivity was not examined, and none of the population in this study was identified as being of African descent. Dukhanina et al⁵¹ showed that a strong quantitative trait locus near Nos2 on chromosome 10 of the rat was linked to blood pressure control, but, using congenic strains of rats, Nos2 did not appear to be involved in hypertension in S rats.⁵¹ Thus, both genetic analyses^50,51 conflict with physiological data, suggesting Nos2 as a gene involved in salt-sensitive hypertension.

In summary, the present study demonstrated that the S714P mutation of NOS2 did not alter the K_m of the enzyme for the substrate, L-arginine, but within the physiological concentration range of L-arginine²⁷ did decrease the amount of NO produced, compared with wild-type NOS2. The findings confirmed that NOS2 was removed from the cytoplasm by the proteasome. Furthermore, accelerated degradation of the S714P mutant through this posttranslational event modulated NOS2 function, suggesting a biochemical explanation for diminished NO production in the S rat in response to an increase in salt intake.^19,25,26,33

	Acknowledgments

 
This work was supported by NIH Grant R01 DK46199 and by the Office of Research and Development, Medical Research Service, Department of Veterans Affairs.

Received January 18, 2001; accepted June 18, 2001.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension. . 1995; 25: 305–313.
2. Weinberger MH, Miller JZ, Luft FC, Grim CE, Fineberg NS. Definitions and characteristics of sodium sensitivity and blood pressure resistance. Hypertension. . 1986; 8 (suppl II): II-127–II-134.
3. Dahl LK. Effects of chronic excess salt feeding: induction of self-sustaining hypertension in rats. J Exp Med. . 1961; 114: 231–236.
4. Dahl LK, Heine M, Tassinari L. Role of genetic factors in susceptibility to experimental hypertension due to chronic excess salt ingestion. Nature. . 1962; 194: 480–482.
5. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. . 1980; 288: 373–376.
6. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA. . 1987; 84: 9265–9269.
7. Gardiner SM, Compton AM, Bennett T, Palmer RMJ, Moncada S. Control of regional blood flow by endothelium-derived nitric oxide. Hypertension. . 1990; 15: 486–492.
8. Wilcox CS, Welch WJ, Murad F, Gross SS, Taylor G, Levi R, Schmidt HHHW. Nitric oxide synthase in macula densa regulates glomerular capillary pressure. Proc Natl Acad Sci USA. . 1992; 89: 11993–11997.
9. Mohaupt MG, Elzie JL, Ahn KY, Clapp WL, Wilcox CS, Kone BC. Differential expression and induction of mRNAs encoding two inducible nitric oxide synthases in rat kidney. Kidney Int. . 1994; 46: 653–665.
10. Markewitz BA, Michael JR, Kohan DE. Cytokine-induced expression of a nitric oxide synthase in rat renal tubule cells. J Clin Invest. . 1993; 91: 2138–2143.
11. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. . 1987; 327: 524–526.
12. Tolins JP, Shultz PJ. Endogenous nitric oxide synthesis determines sensitivity to the pressor effect of salt. Kidney Int. . 1994; 46: 230–236.
13. Deng X, Welch WJ, Wilcox CS. Renal vasoconstriction during inhibition of NO synthase: effects of dietary salt. Kidney Int. . 1994; 46: 639–646.
14. Kone BC, Higham S. Nitric oxide inhibits transcription of the Na⁺-K⁺-ATPase ₁-subunit gene in an MTAL cell line. Am J Physiol. . 1999; 276 (4 pt 2):F614–F621.
15. Plato CF, Stoos BA, Wang D, Garvin JL. Endogenous nitric oxide inhibits chloride transport in the thick ascending limb. Am J Physiol. . 1999; 276 (1 pt 2):F159–F163.
16. Garvin JL, Hong NJ. Nitric oxide inhibits sodium/hydrogen exchange activity in the thick ascending limb. Am J Physiol. . 1999; 277 (3 pt 2):F377–F382.
17. Mattson DL, Lu S, Nakanishi K, Papanek PE, Cowley AW Jr. Effect of chronic renal medullary nitric oxide inhibition on blood pressure. Am J Physiol. . 1994; 266 (5 pt 2):H1918–H1926.
18. Bech JN, Nielsen CB, Ivarsen P, Jensen KT, Pedersen EB. Dietary sodium affects systemic and renal hemodynamic response to NO inhibition in healthy humans. Am J Physiol. . 1998; 274 (5 pt 2):F914–F923.
19. Chen PY, Sanders PW. L-Arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest. . 1991; 88: 1559–1567.
20. Shultz PJ, Tolins JP. Adaptation to increased dietary salt intake in the rat: role of endogenous nitric oxide. J Clin Invest. . 1993; 91: 642–650.
21. Rudd MA, Trolliet M, Hope S, Scribner AW, Daumerie G, Toolan G, Cloutier T, Loscalzo J. Salt-induced hypertension in Dahl salt-resistant and salt-sensitive rats with NOS II inhibition. Am J Physiol. . 1999; 277 (2 pt 2):H732–H739.
22. Salazar FJ, Alberola A, Pinilla JM, Romero JC, Quesada T. Salt-induced increase in arterial pressure during nitric oxide synthesis inhibition. Hypertension. . 1993; 22: 49–55.
23. Deng A, Baylis C. Locally produced EDRF controls preglomerular resistance and ultrafiltration coefficient. Am J Physiol. . 1993; 264 (2 pt 2):F212–F215.
24. Chen PY, St. John PL, Kirk KA, Abrahamson DR, Sanders PW. Hypertensive nephrosclerosis in the Dahl/Rapp rat: initial sites of injury and effect of dietary L-arginine administration. Lab Invest. . 1993; 68: 174–184.
25. Chen PY, Sanders PW. Role of nitric oxide synthesis in salt-sensitive hypertension in Dahl/Rapp rats. Hypertension. . 1993; 22: 812–818.
26. Chen PY, Gladish RG, Sanders PW. Vascular smooth muscle nitric oxide synthase anomalies in Dahl/Rapp salt-sensitive rats. Hypertension. . 1998; 31: 918–924.
27. Wood PA, Hamm DA, Chen PY, Sanders PW. Studies of arginine metabolism and salt-sensitivity in the Dahl/Rapp rat models of hypertension. Mol Genet Metab. . 1998; 64: 80–83.
28. Bosse HM, Böhm R, Resch S, Bachmann S. Parallel regulation of constitutive NO synthase and renin of rat kidney under various stimuli. Am J Physiol. . 1995; 269 (6 pt 2):F793–F805.
29. Mattson DL, Higgins DJ. Influence of dietary sodium intake on renal medullary nitric oxide synthase. Hypertension. . 1996; 27 (3 pt 2):688–692.
30. Ying W-Z, Sanders PW. Dietary salt enhances glomerular endothelial nitric oxide synthase through TGF-ß1. Am J Physiol. . 1998; 275 (1 pt 2):F18–F24.
31. Morrissey JJ, McCracken R, Kaneto H, Vehaskari M, Montani D, Klahr S. Location of an inducible nitric oxide synthase mRNA in the normal kidney. Kidney Int. . 1994; 45: 998–1005.
32. Ying W-Z, Sanders PW. Dietary salt increases endothelial nitric oxide synthase and TGF-ß1 in rat aortic endothelium. Am J Physiol. . 1999; 277 (4 pt 2):H1293–H1298.
33. Barton M, Vos I, Shaw S, Boer P, D’Uscio LV, Gröne H-J, Rabelink TJ, Lattmann T, Moreau P, Lüscher TF. Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension: mechanisms of renal artery endothelial dysfunction and role of endothelin for vascular hypertrophy and glomerulosclerosis. J Am Soc Nephrol. . 2000; 11: 835–846.
34. Tan DY, Meng S, Cason GW, Manning RD Jr. Mechanisms of salt-sensitive hypertension: role of inducible nitric oxide synthase. Am J Physiol. . 2000; 279: R2297–R2303.
35. Radomski MW, Palmer RMJ, Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci USA. . 1990; 87: 10043–10047.
36. Ying W-Z, Sanders PW. Dietary salt modulates renal production of transforming growth factor-ß in rats. Am J Physiol. . 1998; 274 (4 pt 2):F635–F641.
37. Ying W-Z, Sanders PW. Expression of Tamm-Horsfall glycoprotein is regulated by dietary salt in rats. Kidney Int. . 1998; 54: 1150–1156.
38. Yui Y, Hattori R, Kosuga K, Eizawa H, Hiki K, Kawai C. Purification of nitric oxide synthase from rat macrophages. J Biol Chem. . 1991; 266: 12544–12547.
39. Richards MK, Marletta MA. Characterization of neuronal nitric oxide synthase and a C415H mutant, purified from a baculovirus overexpression system. Biochemistry. . 1994; 33: 14723–14732.
40. Hevel JM, White KA, Marletta MA. Purification of the inducible murine macrophage nitric oxide synthase. J Biol Chem. . 1991; 266: 22789–22791.
41. Schmidt HHHW, Pollock JS, Nakane M, Gorsky LD, Förstermann U, Murad F. Purification of a soluble isoform of guanylyl cyclase-activating-factor synthase. Proc Natl Acad Sci USA. . 1991; 88: 365–369.
42. Bredt DS, Hwang PM, Snyder SH. Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature. . 1990; 347: 768–770.
43. Balkovetz DF, Pollack AL, Mostov KE. Hepatocyte growth factor alters the polarity of Madin-Darby canine kidney cell monolayers. J Biol Chem. . 1997; 272: 3471–3477.
44. Balkovetz DF, Sambandam V. Dynamics of E-cadherin and -catenin complexes during dedifferentiation of polarized MDCK cells. Kidney Int. . 1999; 56: 910–921.
45. Craiu A, Gaczynska M, Akopian T, Gramm CF, Fenteany G, Goldberg AL, Rock KL. Lactacystin and clasto-lactacystin ß-lactone modify multiple proteasome ß-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem. . 1997; 272: 13437–13445.
46. Dick LR, Cruikshank AA, Grenier L, Melandri FD, Nunes SL, Stein RL. Mechanistic studies on the inactivation of the proteasome by lactacystin. J Biol Chem. . 1996; 271: 7273–7276.
47. Dick LR, Cruikshank AA, Destree AT, Grenier L, McCormack TA, Melandri FD, Nunes SL, Palombella VJ, Parent LA, Plamondon L, Stein RL. Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. J Biol Chem. . 1997; 272: 182–188.
48. Felley-Bosco E, Bender FC, Courjault-Gautier F, Bron C, Quest AFG. Caveolin-1 down-regulates inducible nitric oxide synthase via the proteasome pathway in human colon carcinoma cells. Proc Natl Acad Sci USA. . 2000; 97: 14334–14339.
49. Julier C, Delépine M, Keavney B, Terwilliger J, Davis S, Weeks DE, Bui T, Jeunemaître X, Velho G, Froguel P, Ratcliffe P, Corvol P, Soubrier F, Lathrop GM. Genetic susceptibility for human familial essential hypertension in a region of homology with blood pressure linkage on rat chromosome 10. Hum Mol Genet. . 1997; 6: 2077–2086.
50. Glenn CL, Wang WYS, Morris BJ. Different frequencies of inducible nitric oxide synthase genotypes in older hypertensives. Hypertension. . 1999; 33: 927–932.
51. Dukhanina OI, Dene H, Deng AY, Choi CR, Hoebee B, Rapp JP. Linkage map and congenic strains to localize blood pressure QTL on rat chromosome 10. Mamm Genome. . 1997; 8: 229–235.

This article has been cited by other articles:

				W.-Z. Ying, H.-G. Zhang, and P. W. Sanders EGF Receptor Activity Modulates Apoptosis Induced by Inhibition of the Proteasome of Vascular Smooth Muscle Cells J. Am. Soc. Nephrol., January 1, 2007; 18(1): 131 - 142. [Abstract] [Full Text] [PDF]

				W.-Z. Ying and P. W. Sanders Enhanced expression of EGF receptor in a model of salt-sensitive hypertension Am J Physiol Renal Physiol, August 1, 2005; 289(2): F314 - F321. [Abstract] [Full Text] [PDF]

				H.-J. Habisch, A. C. F. Gorren, H. Liang, R. C. Venema, J. F. Parkinson, K. Schmidt, and B. Mayer Pharmacological Interference with Dimerization of Human Neuronal Nitric-Oxide Synthase Expressed in Adenovirus-Infected DLD-1 Cells Mol. Pharmacol., March 1, 2003; 63(3): 682 - 689. [Abstract] [Full Text] [PDF]

				Y. Osawa, E. R. Lowe, A. C. Everett, A. Y. Dunbar, and S. S. Billecke Proteolytic Degradation of Nitric Oxide Synthase: Effect of Inhibitors and Role of hsp90-Based Chaperones J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 493 - 497. [Abstract] [Full Text] [PDF]

				M. Szentivanyi Jr., A.-P. Zou, D. L. Mattson, P. Soares, C. Moreno, R. J. Roman, and A. W. Cowley Jr. Renal medullary nitric oxide deficit of Dahl S rats enhances hypertensive actions of angiotensin II Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2002; 283(1): R266 - R272. [Abstract] [Full Text] [PDF]

				J. Loscalzo Salt-Sensitive Hypertension and Inducible Nitric Oxide Synthase: Form-Function Dichotomy of a Coding Region Mutation, Mutatis Mutandis Circ. Res., August 17, 2001; 89(4): 292 - 294. [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 89/4/317    most recent hh1601.094625v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ying, W.-Z. Articles by Sanders, P. W. Search for Related Content PubMed PubMed Citation Articles by Ying, W.-Z. Articles by Sanders, P. W. Related Collections Animal models of human disease Hypertension - basic studies Physiological and pathological control of gene expression